Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

NCT05882058 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05882058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05882058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Recruiting
Start date
October 13, 2023
Completion date
June 8, 2028
Enrollment
204 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

extra-pulmonary neuroendocrine carcinoma, neuroendocrine neoplasms, small cell lung carcinoma